Vedolizumab was used to treat pediatric patients with intestinal inflammation. 1. Requirement 1: A method of treating intestinal inflammation in pediatric patients, including intravenous injection of 200 mg of antibody with special symptoms in pediatric patients with intestinal inflammation (IBD). The binding aperture of human A4B7 Integrina was 200 mg antibody in the second dose within two weeks after the first dose and 200 mg antibody in the third dose within six weeks after the first dose.Antibodies include variable region sequences of amino acid heavy chain 20-140 listed in Chemical Abstract No. 1 and variable region sequences of amino acid light chain 20-131 listed in Chemical Abstract No. 2. Claim 2: The method of claim 1 also includes a fourth dose of 200 mg within 14 weeks of the first dose. Claim 3: Processing of claim 1 or 2, including subsequent use of 200 mg every eight weeks. Proposition 4: The method of any of the above propositions,The heavy chain of the antibody includes the light chain antibody of the 1st SEQ 20-470 amino acid and the 2nd SEQ 20-238 amino acid. Requirement 5: Any of the methods required above, i. e. about 120 minutes for each dose.Métodos para el tratamiento de pacientes pediátricos con enfermedad intestinal inflamatoria mediante el uso de vedolizumab. Reivindicación 1: Un método para tratar la enfermedad intestinal inflamatoria en un paciente pediátrico, que comprende la administración intravenosa a un paciente pediátrico que tenga una enfermedad intestinal inflamatoria (IBD): de una primera dosis de 200 mg de un anticuerpo que tiene especificidad de unión para integrina a4b7 humana, una segunda dosis de 200 mg del anticuerpo dos semanas después de la primera dosis y una tercera dosis de 200 mg del anticuerpo seis semanas después de la primera dosis, donde el anticuerpo comprende una secuencia de región variable de cadena pesada de aminoácidos 20 a 140 de la SEQ ID Nº 1 y una secuencia de región variable de cadena ligera de aminoác
